Please login to the form below

Not currently logged in

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October


The Medicines and Healthcare products Regulatory Agency (MHRA) has approved to the extend the terms of the marketing authorisation for LEO Pharma’s Adtralza (tralokinumab) to include the treatment of adolescent patients, aged 12 years and older, with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy.

The changes were also approved by the European Commission (EC) in October this year, a decision applicable to all EU member states, including Ireland and Northern Ireland, as well as Iceland, Norway and Liechtenstein.

Adtralza is a high affinity, human monoclonal antibody developed to specifically bind to and inhibit the interleukin (IL)-13 cytokine, which plays an important role in the immune and inflammatory processes underlying AD symptoms.

The company’s application was supported by results from the ECZTRA 6 clinical trial evaluating the efficacy, safety and tolerability of Adtralza (150mg or 300mg) monotherapy compared to placebo in 301 AD patients aged 12 to 17 years, with 289 – 195 Adtralza patients and 94 placebo patients – in the full analysis set.

The recommended dose for adolescent patients is an initial dose of 600mg followed by 300mg administered every other week, which is the same as for adult patients.

AD is a chronic, inflammatory skin disease characterised by intense itch and eczematous lesions, and a result of skin barrier dysfunction and immune dysregulation. Approximately 6% of adolescents aged 12 to 17 years have AD in the UK.

Research has shown that moderate-to-severe AD can take a physical, psychosocial and emotional toll on adolescent patients, and there is a significant unmet need for well-tolerated and effective treatments.

“AD is an underestimated condition that has a significant impact on a young person’s quality of life. The extended approval of [Adtralza] for the treatment of adolescents with AD is an important development, giving dermatologists more treatment options for this group of patients,” said Dr James Halpern, consultant dermatologist for Dermatology at Walsall Healthcare NHS Trust.

Also commenting on the approval, Sarah Kleinpeter, vice president and general manager of UK and Ireland at LEO Pharma, said: “We are pleased that adolescents between 12 to 17 years-of-age living with AD will now have more treatment options available to them. LEO Pharma is committed to working with regulatory authorities to make tralokinumab available to all patients who need it.”

To date, tralokinumab is also approved for the treatment of adults with moderate-to-severe atopic dermatitis in Canada, the UAE and Switzerland. It is also approved for adults in the US under the trade name Adbry.

Article by
Emily Kimber

30th November 2022

From: Research, Regulatory



Subscribe to our email news alerts

Featured jobs


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...